A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
NCT04904913 on ClinicalTrials.gov · last registry update 2025-11-17
An unusually large phase 2: 328 participants, more than double the 110 typical for the stage. The sponsor logged completion for 29 March 2023. Primary outcome, as filed: Percent Change from Baseline in Body Weight. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 328
- Started
- 2021-06-08
- Primary completion
- 2023-03-29 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change from Baseline in Body Weight
Conditions studied
Overweight/ Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.